| Autor: |
Chee Lan Lau, Petrick Periyasamy, Muhd Nordin Saud, Sarah Anne Robert, Lay Yen Gan, Suet Yin Chin, Kiew Bing Pau, Shue Hong Kong, Farah Waheeda Tajurudin, Mei Kuen Yin, Sheah Lin Ghan, Nur Jannah Azman, Xin Yun Chua, Poy Kei Lye, Stephanie Wai Yee Tan, Dexter Van Dort, Ramliza Ramli, Toh Leong Tan, Aliza Mohamad Yusof, Saw Kian Cheah, Wan Rahiza Wan Mat, Isa Naina-Mohamed |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Antibiotics; Volume 11; Issue 9; Pages: 1172 |
| ISSN: |
2079-6382 |
| DOI: |
10.3390/antibiotics11091172 |
| Popis: |
Excessive antibiotic consumption is still common among critically ill patients admitted to intensive care units (ICU), especially during the coronavirus disease 2019 (COVID-19) period. Moreover, information regarding antimicrobial consumption among ICUs in South-East Asia remains scarce and limited. This study aims to determine antibiotics utilization in ICUs by measuring antibiotics consumption over the past six years (2016–2021) and specifically evaluating carbapenems prescribed in a COVID-19 ICU and a general intensive care unit (GICU) during the second year of the COVID-19 pandemic. (2) Methods: This is a retrospective cross-sectional observational analysis of antibiotics consumption and carbapenems prescriptions. Antibiotic utilization data were estimated using the WHO Defined Daily Doses (DDD). Carbapenems prescription information was extracted from the audits conducted by ward pharmacists. Patients who were prescribed carbapenems during their admission to COVID-19 ICU and GICU were included. Patients who passed away before being reviewed by the pharmacists were excluded. (3) Results: In general, antibiotics consumption increased markedly in the year 2021 when compared to previous years. Majority of carbapenems were prescribed empirically (86.8%). Comparing COVID-19 ICU and GICU, the reasons for empirical carbapenems therapy in COVID-19 ICU was predominantly for therapy escalation (64.7% COVID-19 ICU vs. 34% GICU, p < 0.001), whereas empirical prescription in GICU was for coverage of extended-spectrum beta-lactamases (ESBL) gram-negative bacteria (GNB) (45.3% GICU vs. 22.4% COVID-19 ICU, p = 0.005). Despite microbiological evidence, the empirical carbapenems were continued for a median (interquartile range (IQR)) of seven (5–8) days. This implies the need for a rapid diagnostic assay on direct specimens, together with comprehensive antimicrobial stewardship (AMS) discourse with intensivists to address this issue. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
